Effect of tafluprost eye drop on intra ocular pressure (IOP) and pupil diameter (PD) in the healthy horses

Subject Areas : Veterinary Clinical Pathology

Mahdiyeh Rafiei ¹ , Ahmad asghari ^{2 *} , Seiyed Saeid Ozmaie ³ , Ehsan Torki ⁴

1 - Student of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran.
2 - Associate Professor, Department of Clinical Science, Science and Research Branch, Islamic Azad University, Tehran, Iran.
3 - استادیار گروه علوم درمانگاهی، واحد علوم و تحقیقات، دانشگاه آزاد اسلامی، تهران، ایران.
4 - Veterinarian, Equine Practitioner, Tehran, Iran.

Received: 2022-01-04 Accepted : 2022-02-20 Published : 2022-01-21

Keywords: horse, Pupil, Tafluprost, IOP,

Abstract :

Introduction: Tafluprost is an analogue of PGF2α that reduce the IOP by prostoglandian receptors and increase ocular fluid outflow. The aim of this study was evaluatation of tafluprost effect on IOP in normal horse eye.Material & Methods: fourteen healthy adult female cross-breed (Turkmen-Thoroughbred) horses were used in this study( 3.5 - 10 years old). The horses were randomly devided into two groups. In group A, seven horses received one drop of 0.0015% preservative-free tafluprost (Zioptan®, Akron, Oak pharmaceutical Inc, France) in right eye. In group B, seven horses received one drop of sterile eye drop as placebo(Tearlose®, Sina Darou Laboratories Company, Tehran, Iran) in right eye. IOP and PD was measured by respectively rebound tonometer ( TonoVet®, Finland) and Caliper device ( China) at the baseline , 30 , 60 , 120 ,240 min, 24 and 48 h post instillation.Results: Tafluprost has significant IOP reduction at 30, 60, 120, 240 min, 24 and 48 h after drug administration in treated group. Descriptive statistics revealed that mean IOP decrease in treated eyes from 22±5.4 mmHg to 16.6±1.6 mmHg during 48 hours. Also, the mean PD in treated group at 30, 60, 120 and 240 minutes was significantly lower than the baseline time. there is a significant relationship between drug administration and time (P = 0.0001). Conclusion: Descriptive statistics revealed that mean PD decrease in treated eyes during 48 hours post instillation from 17.9±2.3 mm to 18.2±3.3 mm.

References:

• Abrams, K.L. (2010). Medical and surgical management of the glaucoma patient. Clinical Techniques in Small Animal Practice, 16(1): 71-76.


• Aihara, M. (2010). Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clinical Ophthalmology, 4: 163.


• Akaishi, T., Kurashima, H., Odani-Kawabata, N., Ishida, N. and Nakamura, M. (2010). Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits. Journal of Ocular Pharmacology and Therapeutics, 26(2): 181-186.


• Brooks, D., Garcia, G., Dreyer, E., Zurakowski, D. and Franco-Bourland, R. (1997). Vitreous body glutamate concentration in dogs with glaucoma. American Journal of Veterinary Research, 58(8): 864-867.


• Fattahian, H., Moridpour, R., Mansouri, N., Mansouri, K. and Jazini Dorcheh, M. (2018). Cataract treatment by phacoemulsification in 13 dogs and 4 cats (19 eyes): a clinical report. Veterinary Clinical Pathology, 12(3): 281-289. [In Persian]


• Izumi, N., Nagaoka, T., Sato, E., Mori, F., Takahashi, A., Sogawa, K., et al. (2008). Short-term effects of topical tafluprost on retinal blood flow in cats. Journal of Ocular Pharmacology and Therapeutics, 24(5): 521-526.


• Jabbari, S., Mashayekhi, M. and Hassanpour, A. (2019). The role of genetic indices in determining the race of the Arabian horses.Veterinary Clinical Pathology, 13(2): 187-197. [In Persian]


• Kwak, J., Kang, S., Lee, E.R., Park, S., Park, S., Park, E., et al. (2017). Effect of preservative-free tafluprost on intraocular pressure, pupil diameter, and anterior segment structures in normal canine eyes. Veterinary Ophthalmology, 20(1): 34-39.


• Ota, T., Murata, H., Sugimoto, E., Aihara, M. and Araie, M. (2005). Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Investigative Ophthalmology and Visual Science, 46(6): 2006-2011.


• Ranno, S., Sacchi, M., Brancato, C., Gilardi, D., Lembo, A. and Nucci, P. (2012). A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients. The Scientific World Journal, pp: 1-6.


• Roth, S., Pietrzyk, Z. and Crittenden, A.P. (1993). The effects of enflurane on ocular blood flow. Journal of Ocular Pharmacology, 9(3): 251-256.


• Sarkhoosh, , Ozmaie, S., Asghari, A. and  Jahandideh, A. (2020). Determination of the reference value for intra ocular pressure(IOP) in the Caspian miniature horse. Veterinary Clinical Pathology, 14(2): 147-154. [In Persian]


• Shokoohimand, A., Arfaee, F., Asghari, A. and Khaksar, E. (2020). Effects of topical administration of tafluprost and combination of tafluprost and timolol or tafluprost and betaxolol on Schirmer tear test, intraocular pressure, and pupil size in clinically healthy dogs. International Ophthalmology, 40(10): 2585-2592.


• Takagi, Y., Nakajima, T., Shimazaki, A., Kageyama, M., Matsugi, T., Matsumura, Y., et al. (2004). Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Experimental Eye Research, 78(4): 767-776.


• Wilcock, B.P., Brooks, D.E. and Latimer, C.A. (1991). Glaucoma in horses.Veterinary Pathology, 28(1): 74-78.